US Stock Insider Trading | Ocular Therapeutix Discloses Two Insider Transactions on February 4

2026-02-19 01:08:20

On February 4, 2026, Ocular Therapeutix (OCUL) disclosed two insider transactions. Executive Notman Donald sold 6,035 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Executive	Notman Donald	February 2, 2026	Sell	5,455	9.14	$49,000
February 4, 2026	Executive	Notman Donald	February 4, 2026	Sell	6,035	8.54	$51,500
November 26, 2025	Executive	Heier Jeffrey S.	November 24, 2025	Sell	3,469	12.04	$41,800
November 26, 2025	Director	Dugel Pravin	November 24, 2025	Sell	19,500	12.04	$235,100
November 26, 2025	Executive	Kaiser Peter	November 24, 2025	Sell	3,007	12.02	$36,100
November 26, 2025	Executive	Nayak Sanjay	November 24, 2025	Sell	1,878	12.04	$22,600
November 7, 2025	Executive	Saroj Namrata	November 5, 2025	Sell	25,900	10.74	$277,800
October 10, 2025	Executive	Anderman Todd	October 8, 2025	Sell	11,000	12.34	$137,400
October 6, 2025	Executive	Kaiser Peter	October 2, 2025	Sell	9,653	11.03	$106,500
October 6, 2025	Executive	Heier Jeffrey S.	October 2, 2025	Sell	10,500	11.04	$115,900

[Company Information]

Ocular Therapeutix, Inc. was incorporated on September 12, 2006, in Delaware. The company is a biopharmaceutical firm dedicated to developing and commercializing innovative therapies for eye diseases and conditions to improve vision and quality of life, with a particular focus on retinal diseases. The company’s hydrogel-based biodegradable candidate products are designed to provide sustained drug delivery to the eye. The lead candidate products are the drug-eluting tear duct stent OTX-DP and the insert placed into a natural opening called the tear duct near the nose, OTX-TP. The company’s tear duct plug candidates combine its hydrogel technology with FDA-approved therapeutic drugs to provide sustained ocular drug delivery.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.